The Last-Minute Playbook: Unpacking 2025's Final Market Calls

The Future is Oral: Why Novo Nordisk's Wegovy Pill is a Game-Changer

The Closing Bell: Unpacking Our Final Trades for a Volatile Market

The Closing Bell: Navigating Today's Final Trades with BABA, ZM, NVO, and TJX

Novo Nordisk's Alzheimer's Trial Setback: A Closer Look

The Pharma Gambit: Why Pfizer Might Just Snatch Metsara from Novo's Grasp

Novo Nordisk Secures Future in Liver Disease, Acquires Akero Therapeutics in Landmark Deal

The GLP-1 Revolution: Why the Market's Reaction to Novo Nordisk and Eli Lilly is Lagging

The Final Verdict: Top Stock Picks Poised for Growth